JPH08512292A - 化学療法剤をinvivoで評価する方法 - Google Patents
化学療法剤をinvivoで評価する方法Info
- Publication number
- JPH08512292A JPH08512292A JP6524410A JP52441094A JPH08512292A JP H08512292 A JPH08512292 A JP H08512292A JP 6524410 A JP6524410 A JP 6524410A JP 52441094 A JP52441094 A JP 52441094A JP H08512292 A JPH08512292 A JP H08512292A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- tumor
- encapsulation device
- vivo
- target cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 52
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 34
- 229940127089 cytotoxic agent Drugs 0.000 title claims abstract description 33
- 238000001727 in vivo Methods 0.000 title claims abstract description 22
- 238000005538 encapsulation Methods 0.000 claims abstract description 23
- 238000012216 screening Methods 0.000 claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims description 126
- 239000012510 hollow fiber Substances 0.000 claims description 38
- 210000004881 tumor cell Anatomy 0.000 claims description 34
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 13
- 238000000338 in vitro Methods 0.000 claims description 12
- 238000000502 dialysis Methods 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 238000007920 subcutaneous administration Methods 0.000 claims description 10
- 239000002033 PVDF binder Substances 0.000 claims description 9
- 229920002981 polyvinylidene fluoride Polymers 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 8
- 238000011156 evaluation Methods 0.000 claims description 8
- 229920002492 poly(sulfone) Polymers 0.000 claims description 8
- 238000007912 intraperitoneal administration Methods 0.000 claims description 7
- 229920002678 cellulose Polymers 0.000 claims description 6
- 229920002301 cellulose acetate Polymers 0.000 claims description 6
- 239000007943 implant Substances 0.000 claims description 6
- 241000700159 Rattus Species 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 239000004627 regenerated cellulose Substances 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 239000004743 Polypropylene Substances 0.000 claims description 3
- 201000007455 central nervous system cancer Diseases 0.000 claims description 3
- 208000025997 central nervous system neoplasm Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000037841 lung tumor Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 229920001155 polypropylene Polymers 0.000 claims description 3
- 241001430294 unidentified retrovirus Species 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 229920006243 acrylic copolymer Polymers 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 210000002950 fibroblast Anatomy 0.000 claims description 2
- 210000000265 leukocyte Anatomy 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- -1 polypropylene Polymers 0.000 claims description 2
- 208000023958 prostate neoplasm Diseases 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 241000699800 Cricetinae Species 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 239000004952 Polyamide Substances 0.000 claims 1
- 210000004748 cultured cell Anatomy 0.000 claims 1
- 244000309715 mini pig Species 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229920002647 polyamide Polymers 0.000 claims 1
- 229920000915 polyvinyl chloride Polymers 0.000 claims 1
- 239000004800 polyvinyl chloride Substances 0.000 claims 1
- 238000012360 testing method Methods 0.000 abstract description 30
- 239000000126 substance Substances 0.000 abstract description 27
- 238000010171 animal model Methods 0.000 abstract description 21
- 238000006243 chemical reaction Methods 0.000 abstract description 2
- 241001465754 Metazoa Species 0.000 description 34
- 239000000835 fiber Substances 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 13
- 229940079593 drug Drugs 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 238000011282 treatment Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 238000009792 diffusion process Methods 0.000 description 6
- 238000011068 loading method Methods 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 238000002513 implantation Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 229920000936 Agarose Polymers 0.000 description 4
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 239000003894 surgical glue Substances 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000003200 peritoneal cavity Anatomy 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 239000003104 tissue culture media Substances 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 229960004630 chlorambucil Drugs 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 102000012214 Immunoproteins Human genes 0.000 description 1
- 108010036650 Immunoproteins Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- RFKMCNOHBTXSMU-UHFFFAOYSA-N methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 description 1
- 229960002455 methoxyflurane Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000003106 tissue adhesive Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000010304 tumor cell viability Effects 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0012—Cell encapsulation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- General Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.化学療法剤をin vivoでスクリーニングする方法であって、 一群の標的細胞を含有する少なくとも1種の生体適合性の半透過性カプセル 封入装置を哺乳動物に移植し、前記装置を予め選ばれた期間だけin vivoで維持 する工程; 前記装置を取り出す工程;及び 前記標的細胞を評価する工程 を含む方法。 2.前記哺乳動物を化学療法剤で処理して前記生体適合性の半透過性カプセル封 入装置を前記療法剤に曝す、請求項1の方法。 3.複数のカプセル封入装置を移植する、請求項1の方法。 4.少なくとも1のカプセル封入装置を皮下移植し、そして少なくとも1のカプ セル封入装置を腹腔内移植する、請求項3の方法。 5.前記カプセル封入装置に各々同じ標的細胞を注入する、請求項4の方法。 6.前記カプセル封入装置に各々異なる標的細胞を注入する、請求項4の方法。 7.前記標的細胞が、腫瘍細胞、線維芽細胞、白血球、リンパ球様細胞、培養一 次細胞、細菌、ウィルス感染細胞、酵母及び真菌からなる群から選ばれる、請求 項1の方法。 8.前記腫瘍細胞が、黒色腫、肺腫瘍系、前立腺腫瘍系、卵巣腫瘍系、乳房腫瘍 系、腎臓腫瘍系、結腸腫瘍系、中枢神経系腫瘍系、白血病若しくはリンパ腫細胞 系、腫瘍異種移植片及び新鮮な患者由来腫瘍組織からなる群から選ばれる、請求 項7の方法。 9.前記生体適合性の半透過性カプセル封入装置が、中空ファイバー及び透析チ ュービングからなる群から選ばれる、請求項1の方法。 10.前記中空ファイバーが、ポリスルホン、ポリフッ化ビニリデン、酢酸セルロ ース、ケン化セルロースエステル、ポリプロピレン、ポリアミド及びポリ塩化ビ ニル−アクリルコポリマーからなる群から選ばれる材料から構成される、請求項 9の方法。 11.前記透析チュービングが、再生セルロース及びセルロースエステルからなる 群から選ばれる材料から構成される、請求項9の方法。 12.前記哺乳動物が、マウス、ラット、ハムスター、ミニブタ、ウサギ、ネコ及 びイヌからなる群から選ばれる、請求項1の方法。 13.前記移植工程が、皮下、腹腔内又は臓器内移植を含む、請求項1の方法。 14.前記生体適合性の半透過性カプセル封入装置が、約50,000ダルトン〜 約500,000ダルトンの分子量を有する化合物に対して透過性の材料から構 成される、請求項1の方法。 15.前記生体適合性の半透過性カプセル封入装置が、約50,000ダルトン〜 約500,000ダルトンの分子量を有する化合物に対して透過性の材料から構 成される、請求項9の方法。 16.前記評価工程がin vitroで行われる、請求項1の方法。 17.前記評価工程がin vivoで行われる、請求項1の方法。 18.前記標的細胞がレトロウィルス感染細胞である、請求項7の方法。 19.前記レトロウィルス感染細胞がヒト免疫不全ウィルスを含有する、請求項18 の方法。 20.前記標的細胞が前記哺乳動物内で複製できないウィルスで感染されている、 請求項1の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/058,154 | 1993-05-05 | ||
US08/058,154 US5698413A (en) | 1993-05-05 | 1993-05-05 | Method of evaluating chemotherapeutic agents in vivo |
PCT/US1994/004443 WO1994025074A1 (en) | 1993-05-05 | 1994-04-21 | Method of evaluating chemotherapeutic agents in vivo |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH08512292A true JPH08512292A (ja) | 1996-12-24 |
Family
ID=22015035
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP6524410A Pending JPH08512292A (ja) | 1993-05-05 | 1994-04-21 | 化学療法剤をinvivoで評価する方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US5698413A (ja) |
EP (1) | EP0697892B1 (ja) |
JP (1) | JPH08512292A (ja) |
AT (1) | ATE243532T1 (ja) |
AU (1) | AU697146B2 (ja) |
CA (1) | CA2162165C (ja) |
DE (1) | DE69432861T2 (ja) |
WO (1) | WO1994025074A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010087319A1 (ja) * | 2009-01-27 | 2010-08-05 | アステラス製薬株式会社 | 前立腺癌治療剤として有効な物質のスクリーニング方法 |
JP2017077473A (ja) * | 2015-10-21 | 2017-04-27 | 国立大学法人 東京大学 | マイクロチューブ、マイクロチューブの製造方法、及びマイクロチューブの製造装置 |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6042909A (en) * | 1997-09-03 | 2000-03-28 | Circe Biomedical, Inc. | Encapsulation device |
US6022733A (en) * | 1997-12-02 | 2000-02-08 | Tam; Yun K. | Simulated biological dissolution and absorption system |
US6410307B1 (en) | 1999-03-09 | 2002-06-25 | Acordis Industrial Fibers Gmbh | Membrane module for testing active substances at cells |
US6616912B2 (en) | 2001-01-05 | 2003-09-09 | Spectrum Laboratories, Inc. | Bi-component microporous hollow fiber membrane structure for in vivo propagation of cells |
US20040067540A1 (en) * | 2001-01-09 | 2004-04-08 | Piotr Lassota | Rapid method for screening compounds for in vivo activity |
WO2003046139A2 (en) * | 2001-11-26 | 2003-06-05 | Exelixis, Inc. | CRBs AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHOD OF USE |
CN1655671A (zh) * | 2002-05-30 | 2005-08-17 | 雷文生物技术公司 | 毒理学和剂量预测的动物模型 |
EP1656447A2 (en) * | 2003-05-29 | 2006-05-17 | AstraZeneca AB | Testing cell cycle regulation effect of a compound using a hollow fibre cell implant |
WO2009014150A1 (ja) * | 2007-07-24 | 2009-01-29 | Astellas Pharma Inc. | ベンズイミダゾール誘導体 |
EP2185594B1 (en) | 2007-08-13 | 2016-04-06 | VasGene Therapeutics, Inc. | Cancer treatment using humanized antibodies that bind to ephb4 |
WO2009045370A2 (en) * | 2007-09-28 | 2009-04-09 | Intrexon Corporation | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof |
WO2010042189A2 (en) | 2008-10-08 | 2010-04-15 | Intrexon Corporation | Engineered cells expressing multiple immunomodulators and uses thereof |
CN107976534A (zh) * | 2016-10-21 | 2018-05-01 | 上海立迪生物技术股份有限公司 | 一种抗肿瘤药物快速药效筛选方法及其专用装置 |
EP4161653A1 (en) | 2020-06-03 | 2023-04-12 | Bionecure Therapeutics, Inc. | Trophoblast cell-surface antigen-2 (trop-2) antibodies |
US20230256114A1 (en) | 2020-07-07 | 2023-08-17 | Bionecure Therapeutics, Inc. | Novel maytansinoids as adc payloads and their use for the treatment of cancer |
JP2024504390A (ja) | 2021-01-22 | 2024-01-31 | バイワンキュア セラピューティクス, インコーポレイテッド | 抗her-2/trop-2構築物及びその使用 |
CN117660581A (zh) * | 2022-09-01 | 2024-03-08 | 上海立迪生物技术股份有限公司 | 一种筛选免疫调节药物药效的模型及方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE759911A (fr) * | 1969-12-05 | 1971-05-17 | Worthington Biochem Corp | Produits enzymatiques actifs |
US4324683A (en) * | 1975-08-20 | 1982-04-13 | Damon Corporation | Encapsulation of labile biological material |
US4409331A (en) * | 1979-03-28 | 1983-10-11 | Damon Corporation | Preparation of substances with encapsulated cells |
US4352883A (en) * | 1979-03-28 | 1982-10-05 | Damon Corporation | Encapsulation of biological material |
US4353888A (en) * | 1980-12-23 | 1982-10-12 | Sefton Michael V | Encapsulation of live animal cells |
US4495288A (en) * | 1981-03-13 | 1985-01-22 | Damon Biotech, Inc. | Method of culturing anchorage dependent cells |
CA1265443A (en) * | 1985-09-18 | 1990-02-06 | Elieser Gorelik | Assays for chemotherapeutic agents |
US4892538A (en) * | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
US5416022A (en) * | 1988-08-10 | 1995-05-16 | Cellex Biosciences, Inc. | Cell culture apparatus |
AU7656991A (en) * | 1990-03-30 | 1991-10-30 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Method and composition for growing tumors from few cells |
JP3252361B2 (ja) * | 1991-10-02 | 2002-02-04 | ミルトン・エイチ・リプスキー | インビボにおける癌の治療のアッセイ |
-
1993
- 1993-05-05 US US08/058,154 patent/US5698413A/en not_active Expired - Lifetime
-
1994
- 1994-04-21 DE DE69432861T patent/DE69432861T2/de not_active Expired - Lifetime
- 1994-04-21 AT AT94914886T patent/ATE243532T1/de not_active IP Right Cessation
- 1994-04-21 JP JP6524410A patent/JPH08512292A/ja active Pending
- 1994-04-21 CA CA002162165A patent/CA2162165C/en not_active Expired - Fee Related
- 1994-04-21 WO PCT/US1994/004443 patent/WO1994025074A1/en active IP Right Grant
- 1994-04-21 AU AU67115/94A patent/AU697146B2/en not_active Ceased
- 1994-04-21 EP EP94914886A patent/EP0697892B1/en not_active Expired - Lifetime
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010087319A1 (ja) * | 2009-01-27 | 2010-08-05 | アステラス製薬株式会社 | 前立腺癌治療剤として有効な物質のスクリーニング方法 |
JP2017077473A (ja) * | 2015-10-21 | 2017-04-27 | 国立大学法人 東京大学 | マイクロチューブ、マイクロチューブの製造方法、及びマイクロチューブの製造装置 |
Also Published As
Publication number | Publication date |
---|---|
CA2162165C (en) | 2008-07-08 |
WO1994025074A1 (en) | 1994-11-10 |
EP0697892B1 (en) | 2003-06-25 |
AU6711594A (en) | 1994-11-21 |
AU697146B2 (en) | 1998-10-01 |
DE69432861T2 (de) | 2004-05-19 |
US5698413A (en) | 1997-12-16 |
DE69432861D1 (de) | 2003-07-31 |
EP0697892A1 (en) | 1996-02-28 |
ATE243532T1 (de) | 2003-07-15 |
CA2162165A1 (en) | 1994-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0697892B1 (en) | Method of evaluating chemotherapeutic agents in vivo | |
Xu et al. | Bridging Schwann cell transplants promote axonal regeneration from both the rostral and caudal stumps of transected adult rat spinal cord | |
Provasoli et al. | Experiments on the resynthesis of symbiosis in Convoluta roscoffensis with different flagellate cultures | |
CN108243607A (zh) | 用于免疫疗法的巨噬细胞的遗传工程 | |
KR20200065892A (ko) | 오가노이드의 생체 이식용 조성물 | |
DE69725317T2 (de) | Implantierbare agarose-kollagenkügelchen enthaltende zellen, die ein diffusionsfähiges biologisches produkt bilden und ihre verwendung | |
Zimmer et al. | Mycoplasma-like organisms: occurrence with the larvae and adults of a marine bryozoan | |
Alphey | Studies on the distribution and site location of Nippostrongylus brasiliensis within the small intestine of laboratory rats | |
CN105384826A (zh) | 表达嵌合抗原受体的脐血有核细胞及其应用 | |
CN109479814A (zh) | 抗肺癌肿瘤药物的筛选模型 | |
CN110337446A (zh) | 过继细胞疗法中ccr2+造血干细胞介导的t细胞激活 | |
CN110035742A (zh) | 干细胞仿生微粒 | |
JP3252361B2 (ja) | インビボにおける癌の治療のアッセイ | |
Ey et al. | Heligmosomoides polygyrus: Simple recovery of post-infective larvae from mouse intestines | |
McKenzie et al. | Protection of xenografts by a combination of immunoisolation and a single dose of anti-CD4 antibody | |
Dalmat | Arthropod transmission of rabbit fibromatosis (Shope) | |
CA1249518A (en) | Oral immunization of mammals | |
EP0074119B1 (de) | An menschliche Fibroblastenzellen adaptierte Hepatitis-A-Viren | |
Askenasy et al. | The topologic and chronologic patterns of hematopoietic cell seeding in host femoral bone marrow after transplantation | |
DE69737101T2 (de) | Zusammensetzungen zur gentransfer in das zentrale nervensystem | |
Dineen | The in vivo production of penicillinase by hemolytic Staphylococcus aureus | |
CA3154130A1 (en) | Hydrogel compositions comprising protist cells | |
WO2003045428A2 (de) | Verwendung einer technisch veränderten zelle als vakzine zur behandlung einer tumorerkrankung | |
RU2425148C2 (ru) | Штамм brucella abortus уф-1 для приготовления биологических препаратов для диагностики и специфической профилактики бруцеллеза сельскохозяйственных животных | |
RU2045576C1 (ru) | Способ определения антибиотикочувствительности возбудителя чумы |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051122 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060222 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060424 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060522 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070123 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070523 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20070704 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20070823 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20080124 |